ArticleSAGE open medical case reports2026
Healthy birth after chemotherapy for diffuse large B-cell lymphoma with superior vena cava syndrome in late pregnancy: A case report.
Article in SAGE open medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A young woman in late pregnancy (31 weeks of gestation) was diagnosed with diffuse large B-cell lymphoma, presenting with bilateral cervical and upper thoracic paratracheal lymphadenopathy that led to superior vena cava syndrome. Her clinical presentation included progressively worsening dyspnea and an inability to lie flat. The initial treatment consisted of a combination of rituximab, cyclophosphamide, pirarubicin, vincristine, and dexamethasone and etoposide chemotherapy. After tumor shrinkage and symptomatic improvement, the pregnancy was terminated via cesarean section, yielding a healthy neonate. Although the patient was classified as high-intermediate risk, consolidated autologous hematopoietic stem cell transplantation was not performed due to her young age. Notably, NKG2C+ natural killer cells-potentially representing antitumor reactive lymphocytes-were detected during the initial treatment but eventually became undetectable. Overall, the patient achieved a satisfactory and notable treatment outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.